Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2697-2715
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2697
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2697
Figure 2 Indole-3-acetaldehyde inhibits proliferation of colorectal cancer cells in vitro.
A and B: Growth curves of HCT116 and DLD-1 cells treated with IAAD; C and D: Vitality of HCT116 and DLD-1 cells treated with different concentrations of indole-3-acetaldehyde after 48 h, compared with the control group; E and F: The expression of Ki-67 in the nucleus was determined by immunofluorescence. aP < 0.05, 50 μmol/L indole-3-acetaldehyde treatment group vs control group; bP < 0.01, 50 μmol/L indole-3-acetaldehyde treatment group vs control group; dP < 0.01, 100 μmol/L indole-3-acetaldehyde treatment group vs control group. DAPI: 4’,6-diamidino-2-phenylindole.
- Citation: Dai Z, Deng KL, Wang XM, Yang DX, Tang CL, Zhou YP. Bidirectional effects of the tryptophan metabolite indole-3-acetaldehyde on colorectal cancer. World J Gastrointest Oncol 2024; 16(6): 2697-2715
- URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2697.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i6.2697